github link
Accession IconSRP068924

Cell Cycle-Targeting MicroRNAs as Therapeutic Tools Against Refractory Cancers [SW900 cells]

Organism Icon Homo sapiens
Sample Icon 2 Downloadable Samples
Technology Badge IconIllumina HiSeq 2000

Submitter Supplied Information

Cyclins and cyclin-dependent kinases (CDKs) are hyperactivated in nearly all human tumor types. To identify new approaches for interfering with cyclins/CDKs, we systematically searched for microRNAs (miRNAs) regulating these proteins. We uncovered a group of miRNAs that target nearly all cyclins and CDKs, and demonstrated that these miRNAs are very effective in shutting off cancer cell expansion. By profiling the response of over 120 human cancer cell lines representing 12 tumor types to these cell-cycle-targeting miRNAs, we identified miRNAs particularly effective against triple-negative breast cancers and KRAS-mutated cancers. We also derived expression-based algorithm that predicts response of primary tumors to cell-cycle-targeting miRNAs. Using systemic administration of nanoparticle-formulated miRNAs, we halted tumor progression in seven mouse xenograft models, including three highly aggressive and treatment-refractory patient-derived tumors, without affecting normal tissues. Our results highlight the utility of using cell-cycle-targeting miRNAs for treatment of refractory cancer types. Overall design: RNA-seq for SW900 cells transfected with 25 nM of miR-193a-3p mimic or 25 nM of negative miRNA control (Negative control #2, Ambion).
PubMed ID
Total Samples
Submitter’s Institution
No associated institution
Alternate Accession IDs


Show of 0 Total Samples
Accession Code
Processing Information
Additional Metadata
No rows found